Bendamustine/Rituximab As Induction Therapy In Mcl

Bendamustine/Rituximab as Induction Therapy in MCL

Targeted Oncology

Dr. Villa on Induction Therapy With Bendamustine/Rituximab in MCL

Dr. Patel on Induction Therapy With Bendamustine and Rituximab in MCL

Acalabrutinib in combination with bendamustine & rituximab in treatment-naïve or R/R MCL

VJHemOnc – Video Journal of Hematology & HemOnc

First results of a prospective bendamustine/rituximab trial in patients with MCL

Dr. Villa on Retrospective Data of Bendamustine/Rituximab in MCL

Dr. Wang on Addition of Acalabrutinib to Bendamustine/Rituximab in MCL

Paul Barr, MD: Bendamustine/Rituximab Therapy

Targeted Oncology

Mantle Cell Lymphoma (Case Studies)

Do we really need to transplant young patients with mantle cell lymphoma?

Dr. Villa on Rationale for Examining BR as Induction Therapy in Transplant-Eligible MCL

FL: Switching to Bendamustine/Rituximab at Progression

Targeted Oncology

Dr. Goy on Bendamustine Plus Cytarabine as MCL Treatment

Safety and Efficacy Findings for Acalabrutinib Plus Bendamustine and Rituximab in MCL

Rationale for Combining Acalabrutinib With Bendamustine and Rituximab in MCL

Targeted Oncology

Reporting positive treatment outcomes with bendamustine + rituximab in indolent lymphomas

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Phillips on the Safety of Acalabrutinib Plus Bendamustine/Rituximab in MCL

Real-world data on previously untreated MCL in the US and the SHINE study

VJHemOnc – Video Journal of Hematology & HemOnc

RB/RC induction for mantle cell lymphoma: promising pooled analysis data

VJHemOnc – Video Journal of Hematology & HemOnc

ASH 2010: The role of bendamustine in the treatment of mantle cell lymphomas